Monitor for interim CLARITY trial data in Q4 2026 and any announcements regarding insurance reimbursement decisions, which could serve as near-term catalysts. Absence of hard metrics limits current trading relevance.
Price Chart
Executive Summary
Aclarion issued a shareholder letter from CEO Brent Ness highlighting progress in physician adoption, clinical evidence, and reimbursement efforts for its Nociscan platform. The company emphasized its strong balance sheet with cash runway into 2028 and an upcoming interim readout from the CLARITY trial in Q4 2026. No financial results or material operational metrics were disclosed.
Key Facts
- Aclarion released a shareholder update from CEO Brent Ness outlining 2026 priorities.
- Focus areas include expanding Nociscan adoption, generating clinical evidence, and securing reimbursement in the U.S. and UK.
- Initial interim data from the CLARITY trial expected in Q4 2026.
- Company claims a strong balance sheet with cash runway into 2028.
- No financial figures (revenue, EPS, costs) or patient enrollment numbers were provided.
Financial Impact
No quantifiable financial impact disclosed
Risk Factors
- Forward-looking statements carry high uncertainty; no guarantee of reimbursement approval or trial success.
- Lack of disclosed financials or enrollment data makes it difficult to assess real progress.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3258802 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 19, 2026 9w ago | Insider Cluster | $2.77 $2.64 | ▼ −4.69% | ▼ −2.74% | $1.93 (−30.32%) |
Aug 18, 2026 9w ago | Insider Cluster | $2.60 $2.53 | ▼ −2.67% | ▼ −1.68% | $1.93 (−25.77%) |
Jun 9, 2026 20w ago | Press Release | $3.26 $2.99 | ▼ −8.28% | ▼ −9.73% | $1.93 (−40.80%) |
Jun 8, 2026 20w ago | Press Release | $3.36 $3.07 | ▼ −8.63% | ▼ −10.26% | $1.93 (−42.56%) |
Jun 3, 2026 20w ago | Press Release | $3.49 $3.09 | ▼ −11.46% | ▼ −10.46% | $1.93 (−44.70%) |
Jun 1, 2026 21w ago | Press Release | $3.37 $2.88 | ▼ −14.54% | ▼ −13.24% | $1.93 (−42.73%) |
May 6, 2026 24w ago | Insider Cluster | $3.28 $3.49 | ▲ +6.40% | ▲ +3.62% | $1.93 (−41.16%) |
May 5, 2026 25w ago | Press Release | $3.20 $3.50 | ▲ +9.38% | ▲ +4.42% | $1.93 (−39.69%) |
Apr 22, 2026 26w ago | Press Release | $3.73 $3.20 | ▼ −14.21% | ▼ −17.37% | $1.93 (−48.26%) |
Mar 19, 2026 31w ago | Press Release | $3.26 $3.39 | ▲ +3.99% | ▼ −3.63% | $1.93 (−40.80%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers